Skip to content Skip to footer
Subscribe Now
NEWS

Dualitas Therapeutics and Roche Partner to Advance Novel Bispecific Antibodies for I&I Diseases in a ~$1B Deal

Shots: Dualitas has entered into a research collaboration & license agreement with Roche to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases, using Dualitas' DualScreen Bispecific Discovery Engine As per the deal, Dualitas will receive $36.5M upfront & additional research, development & commercial milestone payments, representing the total deal value of ~$1B, in addition…
September 17, 2026

Read more

NEWS

Tempest Therapeutics Enters Exclusive Option Agreement with Senlang for In Vivo CAR-T Platform and Pipeline

Shots: Senlang has granted Tempest an exclusive option to license its CD7-targeted lentiviral vector platform & in vivo CAR-T portfolio, incl. a BCMA/GPRC5D dual-targeting candidate for R/R MM & additional assets for hematologic malignancies & autoimmune diseases Senlang’s platform uses targeted lentiviral vectors to deliver CAR transgenes to endogenous CD7+ T cells and NK cells,…
September 16, 2026

Read more

NEWS

MannKind and Rose Pharma Partner to Develop ROSE-010 Technosphere for Weight Management

Shots: Rose received exclusive global rights to MannKind’s Technosphere tech to develop & commercialize ROSE-010 Technosphere, a rapid-acting GLP-1 receptor agonist, with initial work focused on formulation re-establishment & optimization, followed by nonclinical & regulatory development MannKind will receive equity in Rose Pharma, the right to receive royalties on potential future net sales & board…
September 9, 2026

Read more

NEWS

Novartis and Alteogen Partner for ALT-B4 to Advance SC Formulations of Multiple Products

Shots: Alteogen has entered into an option & license agreement with Novartis for the development & commercialization of SC products leveraging ALT-B4 powered by Alteogen's Hybrozyme tech As per the deal, Novartis can obtain exclusive rights to develop & commercialize SC formulations of multiple products using Alteogen’s ALT-B4, with Alteogen eligible for ~$3.223B in option…
September 3, 2026

Read more

NEWS

Evotec and Plectonic Partner on Next-Generation T-Cell Engagers for Solid Tumors

Shots: Evotec and Plectonic Biotech have entered a research collaboration to explore a novel immunotherapy approach for solid tumors by combining Plectonic’s programmable Logibody technology with Evotec’s BiTco platform Plectonic’s Logibody uses multi-antigen tumor signatures to selectively activate T cells, while Evotec’s BiTco platform uses a non-blocking CD2 antibody to enhance T-cell activity, tumor killing…
September 2, 2026

Read more

NEWS

Styx Biotechnologies Partner with ZoeNCure Therapeutics to Advance ADC Development

Shots: Styx Biotechnologies has entered into a strategic agreement with ZoeNCure Therapeutics to accelerate selected Styx ADC programs toward first-in-human clinical studies for multiple solid tumor indications The collaboration gives Styx a capital-efficient path to advance selected ADC assets through coordinated preclinical, CMC, regulatory & clinical activities while preserving opportunities for global development & strategic partnering As…
September 2, 2026

Read more

NEWS

LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M

Shots: LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) As per the deal, Tanabe Pharma will receive up to $435M in upfront & near-term milestone payments together with potential downstream milestones and tiered royalties on net…
August 18, 2026

Read more

NEWS

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

Shots: OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening As…
August 17, 2026

Read more

Load more